

31st March 2015

Relationships with Healthcare Professionals in the United Kingdom

Gilead Sciences makes payments to Healthcare Professionals for consultancy and advisory services and provides sponsorship for educational activities that will ultimately benefit the care of patients.

The company has a policy of transparency as an important means of building and maintaining confidence. With effect from 2012, disclosure is therefore made of the total amount of fees paid to consultants for certain services and the total amounts paid to sponsor attendance at meetings organised by third parties.

For the purposes of this disclosure 'Healthcare Professionals' includes all members of the UK medical, dental and nursing professions and administrative staff and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine in the UK.

Gilead Sciences Inc. group of companies has made the following payments to UK Healthcare Professionals between 1 January 2014 and 31 December 2014 ("2014 Disclosure Period"):

Total Fees Paid during the 2014 Disclosure Period to All UK Healthcare Professionals for Consultancy or Advisory Services (including chairing and speaking at meetings, assistance with training and participation in advisory boards) and payment for related accommodation (inside and outside the UK) and overseas travel expenses incurred in connection with such Services

Total Payment: £676,053 (£585,280 in 2013)

Total number of Healthcare Professionals engaged: 298 (282 in 2013)

Total Payments in the 2014 Disclosure Period for all Sponsorships of UK Healthcare Professionals in relation to Attendance at Meetings organised by Third Parties (e.g. national and international scientific congresses) and payment for related accommodation (inside and outside the UK) and overseas travel expenses incurred in attending such Meetings

Total Payment for sponsored attendances by Healthcare Professionals: £182,677 (£153,923 in 2013)

Total number of Healthcare Professional recipients of sponsorship to attend meetings: 365 (216 in 2013)

Joint Working Projects

Hepatitis C Information Resource Project

(1) Imperial College NHS Foundation Trust, (2) the London Joint Working Group on Substance Use and Hepatitis C, (3) Addaction and Gilead Sciences Ltd are engaged in a joint working project to develop an information resource to support people who use drugs in making decisions about hepatitis C testing and accessing specialist assessment for treatment.

All parties have committed resources to support this project, which was completed within 2014.

This project is designed to provide benefits to patients, the NHS and Gilead and, in particular, to:

- Support people who use drugs who may find it difficult to access traditional models of care and for whom a major barrier to accessing care is a lack of information on testing, diagnosis and treatment.
- Raise awareness among workers in the NHS and Drug Treatment Services to ensure success of the care pathway allowing people who use drugs to access high-quality care, support and treatment for hepatitis C.
- Increase uptake of testing and treatment in accordance with clinical guidance.

For further information please contact:

Medical Affairs, Gilead Sciences Ltd:
08000 113 700

Patient experiences of HIV treatment regimens and services

(1) Royal Free NHS Foundation Trust; and (2) Manchester University Hospitals NHS Foundation Trust and Gilead Sciences Ltd are engaged in a joint working project to understand the existing overall patient experience from current HIV treatment regimens and services and the factors that can impact adherence. This project is anticipated to run from July 2013 to January 2014.

The purpose of the joint working project is to implement a validated patient questionnaire, measured by CRT technology, and to report on any findings to enhance overall future patient treatment and service experience while improving outcomes.

This project is designed to provide benefits to patients, the NHS and Gilead and, in particular, to support:

- direct patient involvement in their care;
- greater ability to understand and focus treatment and services on patient-centred outcomes, through understanding of patient perception and experience;
- identification of issues affecting adherence;
- identification of opportunities to free up NHS funds from wasted expenditure not meeting patient needs;
- provision of real world patient experience and feedback related to patient perceptions of their medicines.

For further information please contact:

Medical Affairs, Gilead Sciences Ltd:
08000 113 700

Date of update: March 2015

Gilead Sciences Ltd is a wholly owned subsidiary of Gilead Sciences Inc, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need for life threatening diseases.

London Initiative for Glandular fever HIV Testing (LIGHT)

(1) Guy's and St Thomas' NHS Foundation Trust, (2) King's College Hospital NHS Foundation Trust, (3) Stockwell Group Practice, (4) Southwark Council Department of Public Health, (5) Lambeth Council Integrated Commissioning Team, (6) GSTS Pathology LLP and Gilead Sciences Ltd are engaged in a joint working project to configure existing electronic laboratory ordering software (TQuest®) used by Guy's and St Thomas' NHS Foundation Trust and King's College Hospital NHS Foundation Trust hospital laboratories to include an HIV test (on an opt-out basis) as part of the electronically requested routine glandular-fever screens in primary care.

All parties have committed resources to support this project, which was commenced in 2014 and is expected to complete within 2 years.

The purpose of the joint working project is to implement and monitor the impact of opt-out HIV testing in electronically requested glandular fever screens in primary care practices across Lambeth and Southwark.

This project is designed to provide benefits to patients, the NHS and Gilead and, in particular, to support:

- testing for HIV in a primary care setting to encourage:
 - earlier HIV diagnosis and linkage to care
 - de-stigmatisation of HIV testing through incorporation into routine medical investigations
- implementation of recommendations in clinical guidelines and alignment with the NHS commissioning QIPP agenda
- deliver and monitor care within a setting convenient for patients

For further information please contact:

Medical Affairs, Gilead Sciences Ltd:
08000 113 700

Date of update: March 2015

Gilead Sciences Ltd is a wholly owned subsidiary of Gilead Sciences Inc, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need for life threatening diseases.